Drug
Srp 4045
Srp 4045: highest development phase Phase 3, developed by Sarepta Therapeutics. 2 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Sarepta Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| SRP-4045 NCT02500381 | Phase 3 | Duchenne Muscular Dystrophy |
| SRP-4045 NCT02530905 | Phase 1 | Duchenne Muscular Dystrophy |
Latest
No recent events.
Follow Srp 4045 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.